worldwide sites | contact | help | sitemap

 

 

 

Livestock Products - Pig - ECONOR

Products

Econor® (Valnemulin)

Product information on this website is for Non-U.S. residents only and is provided by Novartis Animal Health Inc. for general purposes only. Many veterinary products listed are available upon prescription only, and not all such products may be available in all countries. The product information is not intended to provide complete medical information. SHOULD YOUR ANIMAL HAVE A MEDICAL CONDITION, PROMPTLY SEE YOUR OWN VETERINARIAN. WE DO NOT OFFER PERSONALIZED MEDICAL DIAGNOSIS OR ANIMAL-SPECIFIC TREATMENT ADVICE. You should always obtain complete medical information about your veterinary product prescription (including their beneficial medical uses and possible adverse effects) by discussing the appropriate use of any veterinary product directly with the prescribing veterinarian.

Veterinary professionals may obtain complete medical information from the product's information leaflet. Information on these products may vary by country. Animal owners and veterinarians should check with local medical resources and regulatory authorities for information appropriate to their country. In addition, current regulations in many countries limit (or even prohibit in some instances) the ability of Novartis Animal Health Inc. to provide information and/or to respond directly to questions regarding its prescription products. Novartis Animal Health Inc., however, will respond to inquiries from and provide information to your qualified health care professional in accordance with local regulations.

Description

Product Type

Oral antibiotic intended for preventive and therapeutic in feed medication in pigs

Description and Composition

Four premixes are available for in-feed application:

  • ECONOR 0.5% Premix contains 0.532 g valnemulin hydrochloride per 100g
  • ECONOR 1% Premix contains 1.065 g valnemulin hydrochloride per 100g
  • ECONOR 10% Premix contains 10.65 g valnemulin hydrochloride per 100g
  • ECONOR 50% Micro Granules contains 53.25 g valnemulin hydrochloride per 100g

Properties

Valnemulin is a bacteriostatic agent, belonging to the group of pleuromutilins. It has a broad spectrum of activity but is particularly active against Brachyspira, Lawsonia and Mycoplasma species. Valnemulin belongs to a category of antibiotics which is not used in human medicine.

Indications

Treatment and prevention of enzootic pneumonia (Mycoplasma hyopneumoniae) infections. It has a synergistic activity with tetracyclines against other primary (Actinobacillus pleuropneumoniae, Bordetella bronchiseptica) and secondary (Pasteurella multocida) respiratory pathogens.

ECONOR is particularly indicated for the control, prevention and treatment of swine dysentery (Brachyspira hyodysenteriae), porcine colonic spirochaetosis (B.pilosicoli) and porcine proliferative enteropathy (Lawsonia intracellularis).

Dosage and Administration

Dosage prevention/treatment swine dysentery (SD) and porcine colonic spirochaetosis (PCS):

Indication

Inclusion level in feed

Recom-mended dosage (mg valnemulin/kg bw/d)

ECONOR 0.5% Premix (kg/ton)

ECONOR 1% Premix (kg/ton)

ECONOR 10% Premix (kg/ton)

ECONOR 50% Micro Granules (kg/ton)

Prevention SD and PCS

25 ppm

1 - 1.5

5.0

2.5

0.25

0.05

Treatment SD and PCS

75 ppm

3 - 4

15.0

7.5

0.75

0.15

Dosage prevention and treatment of porcine proliferative enteropathy (PPE, ileitis):

Indication

Inclusion level in feed

Recom-mended dosage (mg valnemulin/kg bw/d)

ECONOR 0.5% Premix (kg/ton)

ECONOR 1% Premix (kg/ton)

ECONOR 10% Premix (kg/ton)

ECONOR 50% Micro Granules (kg/ton)

Prevention PPE

37.5 ppm

1.5 - 2.25

7.5

3.75

0.375

0.075

Treatment PPE

75 ppm

3 - 4

15.0

7.5

0.75

0.15

Dosage prevention and treatment of enzootic pneumonia (EP):

Indication

Inclusion level in feed

Recom-mended dosage (mg valnemulin/kg bw/d)

ECONOR 0.5% Premix (kg/ton)

ECONOR 1% Premix (kg/ton)

ECONOR 10% Premix (kg/ton)

ECONOR 50% Micro Granules (kg/ton)

Prevention / Treatment EP

200 ppm

10 - 12

40.0

20.0

2.0

0.40

The fixed inclusion levels of ECONOR are effective in the prevention and treatment of clinical disease. Higher dosages or longer duration of treatment may be necessary for complete elimination of infection. The medicated feed should be fed as the sole ration daily for a minimum of 7 days and up to 4 weeks or until signs of disease disappear.

Special Precautions and Warnings

Pigs should not receive products containing ionophores like salinomycin, monensin and narasin, during or at least 5 days before or after treatment with valnemulin.

When mixing ECONOR and handling the final feed containing ECONOR, direct contact with the skin and mucous membranes should be avoided.

Valnemulin should not be administered to rabbits.

Withholding period

Withdrawal periods according to national registrations.

Formulations and Packages

  • ECONOR 0.5% Premix for medicated feed
    Package size of the bags: 5kg / 25kg
  • ECONOR 1% Premix for medicated feed
    Package size of the bags: 1kg / 2.5kg / 25kg
  • ECONOR 10% Premix for medicated feed
    Package size of the bags: 1kg / 25kg
  • ECONOR 50% Micro Granules for medicated feed
    Package size of the bags: 1kg / 25kg

 

SWX

NYSE

 
 

NOVZn

 
 

NVS

Product Availability

Veterinary Symbol

Please note that not all products listed within this site may be available in all countries. Also, prescribing information and indications for products may differ from country to country, so please consult your local veterinarian for local prescribing and any other information you may be interested in.

Locations

Worldmap



Headquartered in Basel, Switzerland, and present in almost 40 countries, Novartis Animal Health employs approximately 2,900 associates worldwide.

Partnerships

Novartis collaborates with many companies and academic institutions to develop new products, acquire platform technologies, and access new markets.

Novartis collaborates with many companies and academic institutions to develop new products, acquire platform technologies, and access new markets.